Debbie Rigby presents the latest in research news Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation In ARISTOTLE study, non-major bleeding was common and substantially less frequent with apixaban than with warfarin. Non-major bleeding was three times more common than major bleeding (12.1% vs 3.8%). Non-major bleeding was less frequent with apixaban
This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.